Omega-3 Supplements Show Promise for Patients With Mild Cognitive Impairment
Although the findings involved just 12 patients over the course of 4 to 17 months, the findings suggest further clinical study of this relatively inexpensive and plentiful supplement should be conducted.
“Prevention of mild cognitive impairment progression is one of the best hopes,” said Milan Fiala, MD, University of California Los Angeles, Los Angeles, California. “In addition to physical and mental exercises recommended by experts, this study suggests that nutrition is equally important.”
Dr. Fiala and colleagues investigated the effects of 4 to 17 months of supplementation with omega-3 fatty acids and antioxidants in 12 patients with MCI, 2 patients with pre-MCI, and 7 patients with Alzheimer disease. They measured the phagocytosis of amyloid-beta 1-42 by flow cytometry and microscopy, the transcription of inflammatory genes by RT-PCR, the production of resolvin D1 by enzyme immunoassay, and the cognitive status by MMSE.
In patients with MCI and pre-MCI, phagocytosis of amyloid-beta by monocytes increased from 530 to 1306 mean fluorescence intensity units. The increase in patients with Alzheimer's disease was not significant.
The lipidic mediator resolvin D1, which stimulates amyloid-beta phagocytosis in vitro, increased in macrophages in 80% of patients with MCI and pre-MCI. The transcription of inflammatory genes' mRNAs was increased in a subgroup of patients with low transcription at baseline, whereas it was not significantly changed in patients with high transcription at baseline.
“We've known for a long time that omega-3 fatty acids and some antioxidants can be beneficial to people with a wide range of health problems, as well as protective for healthy people,” said Gerald Weissmann, MD, New York University, New York, New York. “Now, we know that the effects of these supplements may extend to Alzheimer's disease as well. Although these supplements are considered to be generally safe and are very easy to obtain, full-scale clinical trials are necessary to verify the findings of this research and to identify who might benefit the most.”
SOURCE: Federation of American Societies for Experimental Biology
DG News saves you time by delivering a short list of medical developments worthy of your time and attention. Our advanced algorithms rank clinical content based on hundreds of data points to surface the most important medical advances impacting your practice each week.